Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Nrxp is moving down in sync with rlftf today. That tells me the results of the rlftf board meeting are not the reason the stock is down today. Could be retail investors moving on in frustration, lack of confidence seeping in as there is no decision yet from the FDA on what many viewed as a slam dunk for EUA approval or it could be something else.
This is repurposed news that nrxp is reposting probably because their share price has been dropping. In any case, the Swiss rltf market turned positive, probably as a result of the press release.
It would be great news if they were being treated with aviptadil. Otherwise, not so much for them.
Who wants to volunteer to tell the NYT to pay close attention to NWBO for a potentially front page follow up story?
The FDA is already busy this morning. They've denied approval for this non covid related drug. Article posted 5 minutes ago.
https://www.google.com/amp/s/www.marketwatch.com/amp/story/avenue-therapeutics-iv-tramadol-gets-negative-fda-response-271623669087
So, he's the guy who let the India patent lapse!
Oh wait, that was the guy before him.
From Pat Dude Pit Bull Pat on Yahoo
hey everybody I just got a message back from relief I'm posting the email
Thank you for your inquiry.
We at Relief are concerned about the dramatic COVID-19 situation in India. There is a major need for additional treatment options for patients with COVID-19 in that country, and we know that the Indian pharmaceutical industry is working on various potential therapies to address this acute situation. Relief was not involved in Biophore’s work on aviptadil. We await with interest the outcome of Biophore’s EUA submission for India.
Relief holds a patent covering potential formulations of RLF-100 in various markets around the world. However, this does not include India.
Kind regards,
Relief Therapeutics
Why is mondobiotech referenced when it ceased to exist in 2009?
India doesn't recognize patent rights for internal use inside India.
Whatever it is that you're getting paid to fud it's too much. You're not very good at it.
Remdesivir -big pharma
Aducanumab -big pharma
Just connecting the dots
I have heard the rich and elegant London swells are exceptionally tall but I had no idea. Mostly a bunch of short rounders in my neck of the woods.
It takes both parties in agreement to close a deal. Suppose the company wasn't for sale last year?
The price is moving up ok but the volume says it's not based on any news. I'm guessing speculation on EUA coming soon. Probably from all those folks that made rlftf trending yesterday.
We were in the fight before we declared war with lendlease and supply convoys. In Asia too with the flying tigers.
From Hoid on Yahoo
Trending explained: when an individual searches for a stock, meaning they click the “search” button and type in a stock symbol, yahoo keeps track of that. The most searched stocks are put on a trending list. RLFTF is currently #5 most searched stock on yahoo.
I notice the Swiss relief ticker is also listed a bit further down the page so add that to the level of interest. Also gme (gamestock) is on that list at 248 a share. Seems the redditors are still punishing shorts.
If I read that correctly the study was done in 1992 and there are numerous studies from that time frame cited at the end of the article. Wonder why it wasn't pursued farther.
Thanks for posting. Well worth watching. I started at the 9 minute mark.
LL is getting the academic recognition she deserves and I'm pretty sure that's a direct reference to dcvax in the article.
Don't worry about the money. We can just print trillions more.
Relief Therapeutics Reports that its Collaboration Partner, NRx Pharmaceuticals, has Submitted an Application for Emergency Use Authorization for Aviptadil to the U.S. Food & Drug Administration
https://www.google.com/amp/s/finance.yahoo.com/amphtml/news/relief-therapeutics-reports-collaboration-partner-051000096.html
Your post prompted me to have a look at the imuc chart. What a horror story.
Finally, confirmation the data has been submitted and shared with Relief. To be published in a peer reviewed journal. Hopefully one of the top tier journals but I'm not holding my breath on that. Good news!
And on that news we're green on the Swiss exchange.
Any idea on their timeline for getting the EUA?
FTA
Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the investigational monoclonal antibody therapy sotrovimab [url]for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients[/url(12 years of age and older weighing at least 40 kilograms [about 88 pounds]) with positive results of direct SARS-CoV-2 viral testing and who are at high risk for progression to severe COVID-19, including hospitalization or death
He has a lot of experience developing inhalers, that's for sure.
Oops. You forgot the sarcasm tag.
They'll need to get the share price above 5 dollars for institutional investors.
New drugs to fight COVID-19 developed (peptides)
The peptide-based drugs are now being tested in hamsters at France's pre-clinical and clinical research facility, IDMIT, with promising early results showing they are not toxic and have few side effects. The drugs are also stable and can be stored at room temperature—which would make them easy to distribute.
The study findings have been published overnight in the prestigious journal Nature Cell Discovery.
The two early intervention drugs target how human cells respond to the SARS-CoV-2 virus, instead of the virus itself.
The first peptide-based drug would be given pre-exposure to the virus and help boost the efficacy of vaccines, while the second drug would stop the spread of the virus in already infected cells.
The discovery of the peptide-based drugs was made possible after the researchers uncovered a previously unknown mode of entry that SARS-CoV-2 exploits to invade cells and cause COVID-19 disease.
Laboratory tests show the first peptide-based drug reduces infection by cloaking the ACE2 receptor protein on human cells. The SARS-CoV-2 spike protein uses the ACE2 receptor to bind to and invade cells.
The virus then latches onto the cloaking peptides, which they mistake for human cells—preventing infection.
The lab tests have also shown that if the virus finds its way into cells, the second peptide-drug can block how the virus hijacks the host cell and replicates. It also boosts the immune system's ability to recognise the virus.
https://medicalxpress.com/news/2021-05-drugs-covid-.html
Looks like we'll give back what we gained yesterday based on the Swiss market.
BRPA down sharply on heavy volume. What's up?
The Swiss market is closed today. Whitmonday holiday.
That's Ex's thinking and he's been saying it for quite some time.
The FDA has expressed interest in therapeutics and aviptadil does not impinge on any vaccine profits as it's for covid patients in critical condition, ie. past the point of using a vaccine. I believe aviptadil will be judged and approved solely on the merits.
Interestingly the after market at one website indicates a price of 1.60 from yesterday and another indicates a 1.60 price pre market this morning. Since they're identical I think this is leftover from a trade yesterday at the close. It's immaterial anyway. The stock is going back to the 1.40-1.50 range this morning.
It was near the end of trading. Watch it tomorrow.
Hah. So I was right. Loooong ago. Lol
They will realize income from the exercise of the outstanding warrants at the strike price should the holders choose to do so.
And of course the exercise date has been repeatedly delayed. Maybe not this time.
It's a reference to the pina colada song.